Hardware FixRecommendedDevice not working? Your driver may be the problemCheck updates for common hardware issues.Fix DriversOctober DealsAmazon USOctober deal check: compare before you payAmazon US: current deals, useful picks and tech finds.Check DealsSlow PC?RecommendedPC slow today? Run a repair scan before it gets worseResolve common Windows issues and optimize system performance.Scan Now×
Skip to content
The Finance Base
The Money Desk · Blog
Re:

What Is Reed Jobs’s $200 Million Cancer Venture Fund? Yosemite Explained

Yosemite, Reed Jobs’s oncology-focused firm spun out of Emerson Collective Health, combines research grants with venture investment. Its 2023 debut-fund close and a separate 2026 second-fund raise are distinct.
From TheFinanceBase Team2 min to read
Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

Reed Jobs launched Yosemite in August 2023 as a standalone investment firm focused on cancer research and companies developing oncology-related products. Its debut fund had an announced first close of more than $200 million. Yosemite combines research grantmaking with venture investing; the headline amount is fundraising, not evidence that a cancer treatment works.

What is Yosemite?

Yosemite grew out of Emerson Collective Health, where Jobs had led health work, and spun off as an independent firm. Its launch announcement described an oncology-focused approach that pairs grants for emerging research with venture investment in therapeutics, diagnostics and digital health. The firm said it would also provide flexible funding for incubation and early translation of research toward practical development. Yosemite’s launch announcement described the first close as oversubscribed and above $200 million.

The idea is to support work at different stages: grantmaking can help early research advance, while venture capital can support company formation and development. Those are distinct forms of financing, and neither, by itself, establishes clinical benefit or regulatory approval.

How the two fund announcements differ

The $200 million figure in the 2023 launch story refers to the first close of Yosemite’s debut fund. A later fundraising report concerns a separate, second fund.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.
Fundraising event Amount and status Source and date
Debut fund More than $200 million at an oversubscribed first close Yosemite, August 1, 2023
Second fund More than $200 million raised toward a $350 million target Forbes, January 29, 2026; a dated report, not an independently audited statement

Forbes named Amgen, Memorial Sloan Kettering Cancer Center, MIT and John Doerr among backers of the second fund. The reported amount raised should not be confused with the $350 million target.

What does Yosemite invest in?

Yosemite’s stated focus is the oncology ecosystem, rather than health care broadly. In a July 2026 interview, TechCrunch described the firm as oncology-only and reported that it builds companies from academic research as well as investing in existing ventures. Jobs said about one-third of the second fund would go to companies Yosemite creates itself or builds with academics. TechCrunch’s July 2026 interview provides that strategy detail.

This model can connect academic discoveries with company-building and commercial development. It does not mean that every funded project becomes a company, reaches clinical testing or produces an effective treatment. No comprehensive, independently verified current portfolio or company-by-company clinical status is established in the cited reports.

What does Reed Jobs say the mission is?

Yosemite’s launch announcement framed its mission as making cancer nonlethal in our lifetime. Speaking at TechCrunch Disrupt on September 19, 2023, Jobs said: “All I really care about in this world is making a huge difference for cancer patients and what we do at Yosemite, and what I’ve wanted to do my entire life, is to make cancer nonlethal in our lifetimes.” TechCrunch’s interview reports the remarks. That is an ambition, not a claim that cancer has become nonlethal or that Yosemite-backed work has demonstrated clinical efficacy.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Support on Ko-Fi

Why is it called Yosemite?

TechCrunch reported that the firm is named for the national park where Jobs’s parents married. The interview also covered the firm’s launch and Jobs’s stated motivation.

Best Value

Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.

Leave a Reply

Your email address will not be published. Required fields are marked *

Free tools Windows power users keep installed

One-click scans. No signup required.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

More post from the Money Desk

  1. The Money DeskBlogTheFinanceBase09 OCT 267 minMortgage Escrow FAQs: Taxes, Insurance, Shortages, and Refunds
  2. The Money DeskBlogTheFinanceBase09 OCT 265 minHow Mortgage Escrow Accounts Work and What Homeowners Pay For
  3. The Money DeskBlogTheFinanceBase09 OCT 265 minHow to Read a Stock Chart, Volume and Market-Cap Data
Recommended PC Tool
Recommended PC Tool
Outdated Drivers Are Slowing You DownFree scan - exact matches
Windows Errors? Fix Them Before They SpreadFree repair scan

Two free Windows tools

One Free Minute Could Fix That PC

Before you go - each of these free tools takes about a minute and tackles what quietly slows a Windows PC down.

Special offer. View Outbyte info, uninstall instructions, EULA, and Privacy Policy.